Drug Trial Radar · NCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Jun 18, 2026
Primary completion
Dec 15, 2032
Study completion Aug 17, 2037
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.
Conditions
- Non-small Cell Lung Cancer
Interventions
CalderasibDrug
Tablet for oral administration.
DurvalumabBiological
Solution for intravenous (IV) infusion.
Placebo to MK-1084Other
Placebo to MK-1084.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 6 years
Locations
119 sites in 18 countries. Site status is shown where the registry gives one.
Piedmont Atlanta Hospital ( Site 0121)
Atlanta, Georgia · Recruiting
Low Country Cancer Care ( Site 0155)
Savannah, Georgia · Recruiting
Duly Healthcare ( Site 0158)
Lisle, Illinois · Recruiting
NHO Revive Research Institute LLC ( Site 0118)
Lincoln, Nebraska · Recruiting
Rutgers Cancer Institute of New Jersey ( Site 0100)
New Brunswick, New Jersey · Recruiting
New York Oncology Hematology P.C ( Site 9000)
Albany, New York · Recruiting
WakeMed Raleigh Campus ( Site 0144)
Raleigh, North Carolina · Recruiting
Virginia Cancer Specialists ( Site 0114)
Fairfax, Virginia · Recruiting
Hospital Italiano de Buenos Aires. ( Site 0300)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Clinica Adventista Belgrano ( Site 0304)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0301)
Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0303)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Hospital Britanico de Buenos Aires ( Site 0305)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Sanatorio Parque ( Site 0302)
Rosario, Santa Fe Province, Argentina · Recruiting
Northern Beaches Hospital ( Site 2401)
Frenchs Forest, New South Wales, Australia · Recruiting
Mater Misericordiae Limited ( Site 2402)
South Brisbane, Queensland, Australia · Recruiting
Princess Alexandra Hospital ( Site 2406)
Woolloongabba, Queensland, Australia · Recruiting
Frankston Hospital ( Site 2403)
Frankston, Victoria, Australia · Recruiting
CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 0406)
Fortaleza, Ceará, Brazil · Recruiting
AFECC ASSOCIACAO FEMININA EDUCACAO COMBATE CANCER ( Site 0416)
Vitória, Espírito Santo, Brazil · Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0415)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
CEPON ( Site 0413)
Florianópolis, Santa Catarina, Brazil · Recruiting
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0401)
Barretos, São Paulo, Brazil · Recruiting
Anhui Provincial Cancer Hospital ( Site 2209)
Hefei, Anhui, China · Recruiting
Beijing Cancer hospital ( Site 2217)
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer hospital ( Site 2226)
Beijing, Beijing Municipality, China · Recruiting
Beijing Peking Union Medical College Hospital ( Site 2220)
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital ( Site 2232)
Fuzhou, Fujian, China · Recruiting
Zhongshan Hospital Affiliated to Xiamen University ( Site 2213)
Xiamen, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University. ( Site 2239)
Xiamen, Fujian, China · Recruiting
The First Affiliated Hospital of Guangzhou Medical University ( Site 2211)
Guangzhou, Guangdong, China · Recruiting
The Second Affiliated Hospital of Guilin Medical University ( Site 2212)
Guilin, Guangxi, China · Recruiting
Guangxi Medical University Cancer Hospital ( Site 2202)
Nanning, Guangxi, China · Recruiting
Fourth Hospital of Hebei Medical University ( Site 2201)
Shijiazhuang, Hebei, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2206)
Wuhan, Hubei, China · Recruiting
Hubei Cancer Hospital ( Site 2203)
Wuhan, Hubei, China · Recruiting
The Second Xiangya Hospital Of Central South University ( Site 2207)
Changsha, Hunan, China · Recruiting
Hunan Cancer Hospital ( Site 2214)
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital ( Site 2224)
Nanjing, Jiangsu, China · Recruiting
Shandong Cancer Hospital ( Site 2200)
Jinan, Shandong, China · Recruiting
Showing 40 of 119 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.